The possible teratogenic effects of anticonvulsant drugs has attracted considerable clinical and research interest over a long period. A substantial medical literature has provided convincing evidence for an increased incidence of congenital malformations in the offspring of mothers taking these drugs, and 6-10%, or a two-to three-fold increase, is a generally quoted figure 1, 2 . Over the last two decades the most popular drugs have been sodium valproate and carbamazepine, succeeding but not completely replacing phenobarbitone and phenytoin. Valproate was first licensed for use in the UK in 1974 and the first reports of an increased risk of neural tube defect and cleft palate emerged in 1982/83. Subsequently further non-specific birth defects were described in association with valproate and reports of a characteristic facial phenotype appeared. Despite the growing literature, including papers in major medical journals, anecdotal evidence has suggested that the general awareness of problems associated with the use of these drugs in pregnancy is poor. Many mothers claiming to have affected children, complain at having received little or no information, or were given complete reassurance.
In assessing the teratogenic risks of anticonvulsants research has focused heavily on congenital malformations. However, the anecdotal experience of some clinicians, particularly clinical geneticists who see many dysmorphic children for assessment and diagnosis, points to a possible increased frequency of neurodevelopmental delay. In my practice four children diagnosed with a fetal anticonvulsant syndrome (each had been exposed to sodium valproate and one of the four to carbamazepine in addition) had varying degrees of learning and behaviour problems as well as speech and language delay. 'Expressive' speech delay was more markedly affected than 'receptive', consistent with the findings of Christianson et al. 3 The behaviour disorder of three of these children also had a similar behaviour pattern, consisting of a socially inhibiting fear of strange environments and crowds. Whilst reference has been made to neurodevelopmental outcome in the published literature [3] [4] [5] [6] [7] , there are no controlled studies which allow a definitive conclusion to be drawn.
In the four cases mentioned all had developed significant myopia as pre-school children, which has not been previously reported. These observations justified further clinical research and, with the help of the National Fetal Anti-Convulsant Syndrome Association, the Exeter and Aberdeen FACS Study was conceived. This culminated in clinical assessment of 58 children from 38 families, involving a detailed pregnancy and medical history as well as examination for dysmorphic features and clinical photography, including the parents where possible. Chromosome analysis and Fragile-X syndrome studies were undertaken, or results acquired from their medical records, which in all cases tested were negative. All the clinical photographs were scrutinized by two independent experts besides those of us undertaking the study, and 53 of the children were judged to be affected with a fetal anticonvulsant syndrome. Importantly, major congenital malformations were present in a minority of some 20 children; there were two cases of neural tube defects but not a single case of clefting. A history of learning and behavioural difficulties, however, was clearly documented in the majority-only four subjects had neither a learning or behavioural disorder. The study highlighted some previously unreported features, namely a high frequency of joint laxity, myopia and astigmatism. In some cases a visual defect in older children had not been recognized at all.
Although this study represents biased ascertainment of cases of fetal anticonvulsant syndromes, by virtue of self selection through the patient support group, the results suggest, along with other anecdotal evidence, that neurodevelopmental delay may be a very significant, yet poorly recognized, aspect of fetal exposure to these drugs. And, importantly, our experience suggests these sequelae may occur in the absence of physical birth defects. The implications are very considerable because the burden for affected families, as well as educational and social services, is long term compared with the consequences of a physical birth defect which may be amenable to simple and curative surgical treatment.
Those of us in clinical genetics with an interest in this problem met briefly at our annual meeting last September. This seminar, drawing together representatives from all the relevant medical disciplines, is the outcome. There is an urgent need to discuss the issues across speciality boundaries in order to both identify critical research questions to be addressed and improve services available to all pregnant women on anticonvulsant medication.
The Glasgow experience
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Greater Glasgow Health Board provides services for a population of 912 500. It is likely that 4562-9125 (0.5-1.0%) of these people have epilepsy, approximately half of whom will be female.
Medical services for women with epilepsy are provided by two specialist epilepsy services, three obstetrics units, one paediatric/genetic unit, 624 GPs and their practice teams. Some of these providers also serve populations that extend well beyond Glasgow's boundaries.
As a Glasgow General Practitioner who has worked within one of the specialist units, I am aware of the many problems faced by both women with epilepsy, and service providers in trying to deliver a consistent standard of high-quality care. We currently have a system of care that links poorly across primary, secondary and tertiary services for a variety of reasons. Additionally we need to link more closely with the voluntary sector (in Scotland this is the Epilepsy Association of Scotland), and the social services.
The 'average GP' with 2000 patients cares for between 10 and 12 people with active epilepsy. In a year he can expect to refer two patients with a possible diagnosis of epilepsy, one of whom will turn out to have epilepsy. These small numbers make it difficult for an individual general practitioner to develop expertise with the complex issues involved in caring for women with epilepsy.
In Glasgow we can expect about 50-60 births to women with epilepsy per year. These women are cared for by three obstetric units who each provide care for these patients in different ways. A GP will only care for such a patient once every 12 years.
As it is only the 30% of women with epilepsy which is difficult to control who attend specialist epilepsy units, the majority of women in child-bearing years can expect to have no contact with a specialist prior to and during child-bearing years.
The numbers described above illustrate the formidable organizational issues that need to be overcome. The problems faced by Glasgow are by no means unique and need to be resolved to allow women with epilepsy to receive the best possible care. As part of an ongoing prospective population-based study, detailed information is collected on all pregnant women with epilepsy in the old Northern Region. Over two years 396 women have been notified: of these 70% were on monotherapy, 14% on polytherapy and 16% were on no anticonvulsants. Of those on monotherapy, 52% were on carbamazepine, 35.5% on valproate, 9.5% on phenytoin, 2% on lamotrigene and 1% on phenobarbitone. There were 60% of women receiving care for their epilepsy from their GP. Less than 40% reported receiving advice regarding pregnancy and epilepsy, and this did not rise significantly for multips. Fewer than half were planned pregnancies. Guidelines for folic acid supplementation and vitamin K useage were poorly complied with. There have been two medical terminations for spina bifida, both were taking sodium valproate and one was also taking carbamazepine. Apart from the two cases of spina bifida, there were a number of other malformations amongst the babies exposed to anticonvulsants including one child with phocomelia whose mother was on sodium valproate and one child with short ribs whose mother was on valproate and lamotrigine. Phocomelia is a well-recognised valproate-associated malformation. Rib anomalies have been associated with valproate in both human and animal studies but we are aware of another case of rib anomalies reported in association with lamotrigine and carbamazepine. We have identified four babies with malformations who were not exposed to antiepileptic medication. The overall malformation rate in women with epilepsy was 1.6 times our general population rate, supporting previous observations that this group of women are at high risk of having infants with malformations. Despite this, they currently appear not to receive optimal care. We are trying to address this by a programme of education and the use of guidelines and epilepsy care nurses. We hope to continue a more detailed study of the offspring of these women looking at their developmental outcome and studying any dysmorphic features. Teratogenesis is an important consideration when prescribing antiepileptic drugs (AEDs) in women of child-bearing age. These risks may increase with dosage and the number of AEDs taken. Five new AEDs have been licensed for use in the UK since 1989 with no useful data on their safety in pregnancy although animal studies have been initially reassuring for some. In addition many women are prescribed the newer AEDs in combination with other AEDs which may increase risks. In order to try and address these problems a confidential prospective observational registration and follow-up study of the relative safety of the newer AEDs as been established with ethical approval in the UK since 1996. Any woman with epilepsy, whether currently taking AEDs or not and who becomes pregnant, is eligible for inclusion on the register. Reporting of cases is encouraged from neurologists and other specialists providing epilepsy services, specialist epilepsy nurses, obstetricians, midwives and general practitioners. This year additional funding has allowed the setting up of a freephone number-0800 3891248-to enable eligible women to self refer. To date over 1000 women have been registered (90% prospectively) with outcome data on over 400. Of these 4% took no AED before or during pregnancy and 56% were on monotherapy. A healthy baby was born in 83% pregnancies with a spontaneous pregnancy loss of 12%. Of live births or abortions, 5% have resulted in a major structural birth defect. Lamotrigine was the most frequently prescribed newer AED (N = 109) with a major structural defect occurring in 1 of 43 patients on lamotrigine monotherapy. The remaining monotherapy-associated abnormalities occurred in women on sodium valproate monotherapy (N = 38). All other structural abnormalities reported occurred in patients on polytherapy. We have, therefore, established an effective method for collecting data which in time will allow more accurate counselling of women planning a pregnancy while receiving treatment for epilepsy.
Outcome of pregnancy in women with epilepsy with regard to malformation
UK Epilepsy and pregnancy register
Clinical pharmacology of antiepileptic drugs in pregnancy
George Mawer * , Jill Clayton-Smith † & Helen Coyle * * David Lewis Centre for Epilepsy, Cheshire, UK; † Regional Genetic Service, St Mary's Hospital, Manchester, UK A woman with epilepsy embarking on pregnancy is most likely to be taking carbamazepine or sodium valproate; these are the standard drugs against focal and generalized epilepsies, respectively. Phenytoin use is waning and, when pregnancy is foreseen, there is appropriate caution about the use of the newer drugs introduced since 1989.
Many studies of pregnancy outcome relate to phenobarbitone and phenytoin. Some report increased complications of pregnancy (for example vaginal bleeding, spontaneous abortion, pre-eclampsia, operative delivery and neonatal haemorrhage) but there is much variation between studies.
The incidence of structural defects in the progeny is increased (4-6% compared with 2-3% in the general population); the likelihood of defect increases with the number of drugs taken and with the dose. Omtzigt et al. 1 for example, found an increase in the risk of spina bifida with higher doses of sodium valproate. Monotherapy at the minimum dose for acceptable seizure control is thus recommended.
Since 1975, dysmorphic states with cranio-facial features and mis-aligned digits have been recognised; some may be drugspecific but lack of accepted definitions means the incidence is not known. An association with neuro-developmental delay is suspected and causes special concern.
We have monitored the outcome of pregnancy in patients attending the Central Manchester Epilepsy Clinic since 1990. Infants are assessed by JC-S and graded 1, 2 or 3 for impaired development, dysmorphic features and structural defects. Assessment has been made of 32 of 56 infants; 25 of 32 had been exposed to monotherapy with carbamazepine (8), lamotrigine (2), phenytoin (3) or sodium valproate (12). The incidence of abnormality was higher than that genrally reported in the offspring of mothers with epilepsy-impaired development in 12 of 32 (38%): dysmorphic features in 14 of 32 (44%): structural defects in 7 of 32 (22%)-but the majority of infants were mildly affected (graded 1). Moderate (2) and severe (3) abnormalities were found mainly in the offspring of mothers who conceived whilst receiving sodium valproate at a dose of more than 800 mg day −1 .
Our study has no control group and is biased towards mothers with difficult-to-manage epilepsy. An ideal study would recruit from primary care or hospital antenatal clinics to avoid bias and compare with matched controls; every infant would be assessed. The impact of drug + epilepsy would be revealed but differences due to drugs would still be confounded with differences due to epileptic syndromes. Dose/response relationships within drug-syndrome groups would clarify the role of the drug.
Fetal anticonvulsant syndromes: an overview
Jill Clayton-Smith
Regional Genetic Service, St. Mary's Hospital, Manchester, UK
The incidence of birth defects amongst the children of epileptic mothers is around 6-7%, about twice to three times that of the normal population. There may be serveral reasons for this including genetic predisposition, effect of seizures during pregnancy and teratogenic effects of anticonvulsants used to control the epilepsy. There is now firm evidence for the latter both from animal studies and from clinical studies of exposed infants. The data is, however, incomplete since there have been no good long-term follow-up studies to document in particular the developmental and neuropsychological problems encountered in children exposed to anticonvulsants during pregnancy. This presentation documented the clinical features in a series of patients referred to the Department of Clinical Genetics at St. Mary's Hospital. As such it is anecdotal, and the sample is biased because of the mode of ascertainment. Documentation of the problems in these individuals does, however, aid delineation of the fetal anticonvulsant syndromes.
Fetal phenytoin syndrome was the first anticonvulsant syndrome to be recognised as an entity by Hanson in 1978. Of infants exposed to phenytoin in utero 10% will show significant adverse effects, which include intra-uterine growth retardation, distinctive facies with flat nasal bridge, hypertelorism and prominent cupid's bow to upper lip, cleft lip and palate, congenital heart defects and hypoplasia of the distal phalanges and fingernails. Developmental delay is also a feature. Milder effects will be shown by 30% of infants and the literature suggests that 60% of infants exposed to phenytoin will not show any adverse effects, although no long-term studies have been carried out to follow up development.
Several reports have linked exposure to carbamazepine in utero with birth defects. The commonest birth defects observed include spina bifida and orofacial clefting. Jones et al. (1989) suggested that there was a specific 'carbamazepine face' but observation of our own patients did not confirm this.
Fetal valproate syndrome was the commonest condition observed amongst our own cohort of patients. The pattern of abnormalities seen in infants exposed to valproic acid in utero was documented by DiLiberti et al. (1984) and our observations in a series of infants exposed to valproate monotherapy confirm and extend these findings. The clinical features include characteristic facies with a prominent metopic suture and tall forehead with bifrontal narrowing. There is a flat nasal bridge and epicanthic folds are common in younger children. The eyebrows are often neat and arched, with a medical deficiency, the nose is short and anteverted, there may be a prominent groove of skin below the eyes and the upper lip is thin and the mouth downturned. The lower lip is everted, giving a characteristic facial profile and the philtrum is flat. The face is more obvious in younger children and becomes less remarkable with age. The congenital malformations associated with the syndrome include neural-tube defects, usually low lumbosacral spina bifida, cleft palate and congenital heart disease. (A very specific defect, aberrant origin of the pulmonary artery, was seen in one of our patients). Radial-ray defects are common with high doses of valproate and other limb defects include lobster-claw deformity, and pre-axial polydactyly. The digits may be slim and the toes are frequently overlapping. We remarked that the lower-limb musculature appeared poor in many patients and there was marked joint laxity. Abdominal wall defects, genito-urinary abnormalities and tracheomalacia were also seen. Finally, we have seen three patients with iris coloboma, a complication not hitherto reported in the literature.
The natural history of fetal valproate syndrome was described. Pregnancy is usually uneventful and most infants have a normal birth weight. After birth there may be symptoms of drug withdrawal with jitteriness, hypoglycaemia and feeding difficulty. Thereafter, growth is usually fairly good and most children have normal growth parameters. There is acquired microcephaly in some patients but this is not the rule. Motor milestones are often normal or mildly delayed, with joint laxity causing difficulty with walking. Speech delay is often the first problem which brings children to medical attention. Developmental delay is often not apparent until school age, and the majority of the children we observed were statemented for special educational needs. Finally, several children had been diagnosed to be hyperactive or were on treatment for attention deficit hyperactivity disorder.
We attempted to correlate the degree of problems seen in individual children to the dose of valproate they were exposed to during pregnancy and did this by devising a simple scoring system for adverse effects. This did give a positive correlation with the worst affected infants having been exposed to higher doses. It also indicated that maternal factors seem important, as some mother seem to be able to take relatively high doses of sodium valproate without risk to their offspring, whilst others have children with signs of fetal valproate syndrome even when taking a lower dose.
The fact that some of the features of the fetal valproate syndrome are so specific, e.g. the site of the neural-tube defects, radial-ray defects and specific heart defects, suggests that valproic acid may be interfering in specific developmental pathways rather than acting as a general 'poison' to the embryo. It has been suggested that valproate may interfere in some with the action of specific developmental genes such as the HOX gene group. We showed a fetus with an extra set of ribs, which might support this theory.
Our data, though anecdotal, is of concern, particularly the incidence of developmental and neuropsychological problems which are not apparent in early infancy. Further prospective controlled studies are merited to study these effects in more detail. This study reports the results of a questionnaire survey of female members of the British Epilepsy Association. The women were asked about their concerns with their epilepsy with respect to being female, and in particular asking about information relating to important topics such as contraception and pregnancy. A qeustionnaire was sent to 6000 BEA women members of whom 1855 (31%) replied.
BEA survey of women with epilepsy (Crawford
Of the women 880 (47%) already had children, but one in ten of these were planning to have further children. Overall 441 (23%) of women were planning to have children, 169 (9%) within the next 2 years.
The women were asked about the advice they had received about pregnancy (Table 1) . Six hundred and thirty seven (34%) claimed they had not received any advice and 459 (25%) had not discussed pregnancy with anyone. Amongst those who had already had children, 232 (38%) claimed not to have received any advice about pregnancy and epilepsy and only 210 (24%) had discussed the issues before conception with a doctor. The women planning to have children over the subsequent 2 years received the greatest amount of advice about epilepsy and pregnancy, although 34 (20%) still claimed not to have received any advice. Many women intending to have children in the next 2 years felt they still had unanswered questions relating to their epilepsy and pregnancy and subsequent care of the child ( Table 2 ). The best informed group consisted of those women who had already had children and planned to have more.
In the main, advice was given by hospital specialists (Table 3) . Of women receiving advice 58% stated this was their main source of information. General practitioners were mentioned by a third. Of all the women who received advice, 17% were advised by the British Epilepsy Association (BEA) which might be expected in this group of BEA members. Overall the women felt there was a need for more information about epilepsy and pregnancy. 
